Finance Watch: Kenvue, Acelyrin Launch Biggest Biopharma IPOs Of 2023
SPAC Mergers Still A Go-Public Alternative For Some
Executive Summary
Public Company Edition: J&J’s consumer health spinout Kenvue grossed $3.8bn in its public market debut and Acelyrin raised $540m in an upsized IPO. Also, Seres accessed $250m in new debt for Vowst commercialization while follow-on offerings raised $325m for ImmunoGen and $240m for Morphic.
You may also be interested in...
FibroGen Misses In First Of Two Pivotal DMD Trials
The biotech’s pamrevlumab fails a Phase III study in non-ambulatory Duchenne muscular dystrophy, but the antibody still has a shot in ambulatory DMD, as well as IPF and pancreatic cancer.
Cash Runways Dry Up, Creating A ‘Complex’ Road Ahead For Biotech
More than half of emerging biotech companies have less than two years of cash to fund operations, according to EY’s Beyond Borders report.
Finance Watch: Royalty Deals Pick Up As Alternative Financings Find Appeal
Public Company Edition: Seven companies revealed $2.1bn worth of royalty financings in the first quarter of 2023 and the deals keep coming in Q2, with uniQure monetizing Hemgenix royalties for up to $400m. Also, Legend grossed $350m in a follow-on offering and Athenex is liquidating via bankruptcy.